The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs
Sobos focus on restoring immune balance without relying solely on pharmaceuticals
The unfolded protein response and cell fate control
Yerba Mate The Claims: Some studies suggest yerba mate may stimulate GLP-1 and reduce appetite
These evolving requirements are fostering a digitally secure infrastructure, significantly elevating the demand for blockchain solutions in the healthcare sector GLP-1 Receptor Agonists Obesity Drugs Market Analysis GLP-1 receptor agonists, a class of drugs that mimic the glucagon-such as peptide-1 hormone, are increasingly recognized as powerful therapeutic options for obesity management due to their dual benefits in appetite regulation and blood glucose control, making them essential tools in both endocrinology and weight-loss medicine The accelerating demand for GLP-1 receptor agonists is primarily driven by the global surge in obesity and type 2 diabetes cases, strong clinical outcomes demonstrating significant weight reduction, and growing medical and consumer acceptance of pharmacological obesity treatment North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, characterized by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide, with the U.S
